NORCEPT-E 1/35 28

Post-LOE

ethinyl estradiol; norethindrone

Johnson & Johnson

ANDAORAL-28TABLET

Approved

Feb 1989

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

NORCEPT-E 1/35 28 (ethinyl estradiol; norethindrone) by Johnson & Johnson. Approved for pregnancy. First approved in 1989.

Drug data last refreshed 20h ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications (1)

pregnancy

Company

Worked on NORCEPT-E 1/35 28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.